We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.

AusPAR: Bevacizumab

Australian Public Assessment Report

AusPAR

AusPAR: Bevacizumab [PDF, 416.16 KB]

AusPAR: Bevacizumab [Word, 1.35 MB]

Attachment-01 Product information for Bevacizumab [PDF, 576.14 KB]

Attachment-01 Product information for Bevacizumab [Word, 562 KB]

Attachment-02 Product information for Bevacizumab [PDF, 575.56 KB]

Attachment-02 Product information for Bevacizumab [Word, 248.62 KB]

Device/Product Name

Bevacip/Bevaciptin

Active ingredients

Bevacizumab

AusPAR Date

19 May 2022

Published

31 May 2022

Submission Number

PM-2020-05373-1-4

Submission Type

New biosimilar medicine

Decision

Approved